AMENDMENT NO. 6 TO NOTE PURCHASE AGREEMENTNote Purchase Agreement • September 19th, 2008 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 6 (the “Amendment”), dated and effective as of August 12 , 2008, is by and between INTERLEUKIN GENETICS, INC., a Delaware corporation (the “Company”), and Pyxis Innovations Inc., a Delaware corporation (“Pyxis”).
FIRST AMENDMENT TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • September 19th, 2008 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
THIS FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT, effective August 12 , 2008, by and between INTERLEUKIN GENETICS, INC., a Delaware corporation (the “Company”), and Pyxis Innovations Inc., a Delaware corporation (“Investor”).
EXPLANATORY NOTE: “*” INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED AND SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 19th, 2008 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Michigan
This First Amendment to Exclusive License Agreement (this “Amendment”) is made and entered into effective September 1, 2008, between Interleukin Genetics, Inc., a Delaware corporation having its principal office at 135 Beaver Street, Waltham, MA 02452 (“IG”) and Access Business Group International LLC, having offices at 7575 Fulton Street, East, Ada, Michigan 49355-001 (“ABG”).
